RxDoctor Payments DataLook up a doctor →

Paul Poommipanit, MD

Interventional Cardiology · Cleveland, OHNPI 1487779757

Payments from drug & device makers

$100,552in general payments, 2019–2025

Across 575 payments — averaging $174.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$42K
  • Medtronic$20K
  • Asahi Intecc USA, Inc.$16K
  • Abiomed$7K
  • Biotronik Inc.$6K
  • Boston Scientific$2K
  • plus $6K from 33 others
$134in research payments, 2019–2025

Across 1 payment — averaging $134.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$134

What the payments were for

  • Consulting fees$45,93547%
  • Speaking & faculty fees$27,50028%
  • Travel & lodging$7,7698%
  • Food & beverage$15,63716%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,552 in reported general payments places this provider in the 80th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$136,159
Medicare patients
557
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$140,873
Repatha SureclickEvolocumab87$97,901
XareltoRivaroxaban46$49,631
EntrestoSacubitril/Valsartan26$46,576
JardianceEmpagliflozin39$33,423
BrilintaTicagrelor32$22,934
Praluent PenAlirocumab16$18,695
FarxigaDapagliflozin Propanediol14$10,007
Atorvastatin Calcium445$4,264
Metoprolol Succinate317$3,695
ClopidogrelClopidogrel Bisulfate396$3,630
Ranolazine ErRanolazine18$3,526
Amiodarone Hcl11$2,180
Prasugrel Hcl18$1,519
Losartan Potassium139$1,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$457$140,873137 claims
Johnson & JohnsonXarelto$632$49,63146 claims
NovartisEntresto$1,177$46,57626 claims
Boehringer IngelheimJardiance$28$33,42339 claims
AstraZenecaBrilinta, Farxiga$815$32,94146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →